期刊文献+

DOF和DOX方案治疗不可切除晚期胃癌的不良反应的对比分析 被引量:5

Contrastive analysis of the foxic and adverse reaction of DOF vs DOX in the treatment of advanced unresectable gastric cancer
暂未订购
导出
摘要 目的:对比研究DOF和DOX方案治疗晚期胃癌的不良反应差异。方法:回顾性分析69例不可切除晚期胃癌患者,其中31例采用DOF方案化疗(奥沙利铂+多西他赛+5-氟尿嘧啶化疗,DOF组),38例采用DOX方案化疗(奥沙利铂+多西他赛+希罗达化疗,DOX组),比较2组间不良反应发生率和严重程度的差别。结果:每组每位患者均完成3~8个周期,DOF组共完成189个周期,DOX组共完成233个周期。以周期统计的不良反应总发生率2组相当,分别为80.0%和81.5%(P〉0.05);但血液系统不良反应总发生率DOF组高于DOX组,尤以中性粒细胞减少及血小板下降表现明显,发生率分别为48.7%〉33.5%和33.3%〉18.0%(P〈0.05)。非血液系统不良反应总发生率2组相仿(P〉0.05),但口腔黏膜损害和周围静脉炎的发生率DOF组较高,手足综合征及指甲损坏发生率DOX组较高,发生率分别为:41.8%〉15.0%、16.4%〉3.4%、6.9%〈50.6%及4.8%〈36.5%(均P〈0.05)。以患者例数统计的不良反应总发生率和非血液系统不良反应总发生率2组相仿(P〉0.05),而血液系统不良反应总发生率和I/IV度的比例DOF组较高(P〈0.05)。结论:DOF和DOX方案不良反应发生率总体相当;但DOF方案易出现血细胞下降、口腔黏膜损害和周围静脉炎,且I/IV度比例高,而DOX方案易出现手足综合征和指甲损害等不良反应。 Objective: To contrastive study the toxic and adverse events of DOF and DOX scheme in the treatment of advanced unresectable gastric cancer. Methods: Clinical data of 69 advanced gastric cancer, includ- ing 31 treated in DOF and 38 in DOX, were analyzed retrospectively in order to compare the adverse event rates and severity level in both groups. Results: Both groups underwent 3 to 8 cycles, there were 189 cycles in DOF and 233 cycles in DOX respectively. The total adverse event rates were undifferentiated at 80.0% and 81.5% when statistical analyzed by cycles (P〉0.05). But the total hematologic toxicity in DOF were higher than those in DOX, especially neutropenia and thrombocytopenia which respectively were 48.7% vs 33.5% and 33.3% vs 18.0% (P〈0.05). Though the total non-hematologic toxicity were similar in both groups, the stomatitis and peripheral phlebitis were higher in the former, while opposite to the hand-foot syndrome and nail toxicity, the rates respectively were 41.8% vs 15.0%, 16,4% vs 3.4%, 6.9% vs 50.6% and 4.8% vs 36.5% (P〈0.05). We concluded the same results that the total hematologic toxicity and its 3/4 grade in DOF were higher than those in DOX (P〈0.05), however the total adverse event rates and the total non-hematologic toxicity were similar in both groups (P〉0.05), while the data were statistical analyzed by patients. Conclusion: Though the total adverse event rates are undifferentiated, the hematologic toxicity, stomatitis and peripheral phlebitis are more frequently oc- curred in DOF. and the hand-foot syndrome and nail toxicitv are hieher in DOX.
出处 《温州医科大学学报》 CAS 2016年第1期60-64,共5页 Journal of Wenzhou Medical University
关键词 胃肿瘤 奥沙利铂 多西他赛 氟尿嘧啶 卡培他滨 stomach neoplasms oxaliplatin docetaxel fluorouracil capecitabine
  • 相关文献

参考文献4

二级参考文献70

  • 1Javier Sastre,Jose Angel García-Saenz,Eduardo Díaz-Rubio.Chemotherapy for gastric cancer[J].World Journal of Gastroenterology,2006,12(2):204-213. 被引量:22
  • 2王玲,焦智民,李平.中药内服外洗治疗希罗达所致中重度手足综合征8例[J].中医研究,2006,19(4):41-43. 被引量:39
  • 3Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 4LEE S D,KIM H J,HWANG S J,et al.Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine:a case report[J].The Korean J Intern Med,2007,22(2):109-112.
  • 5LIN E,MORRIS J S,AYERS G D.Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumot activity[J].Oncology(Huntingt),2002,16(12):31-37.
  • 6MILANO G,ETIENNE GRIMALDI M C,MARI M,et al.Candidate mechanisms for capecitabine-related hand-foot syndrome[J].Br J Clin Pharmacol,2008,66(1):88-95.
  • 7HONDA J,SASA M,MORIYA T,et al.Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results[J].J Med Invest,2008,55(1-2):54-60.
  • 8ASGARI M M,HAGGERTY J G,MCNIFFJ M,et al.Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors[J].J Cutan Pathol,1999,26(6):287-294.
  • 9MROZEK ORLOWSKI M E,FRYE D K,SANBORN H M.Capecitabine:nursing implications of a new oral chemotherapeutic agent[J].Oncol Nurs Forum,1999,26(4):753-762.
  • 10HESS V,SALZBERG M,BORNER M,et al.Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma:a phase Ⅰ/Ⅱ trial[J].J Clin Oncol,2003,21(1):66-68.

共引文献30

同被引文献48

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部